Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Holdings Decreased by Speece Thorson Capital Group Inc.

Speece Thorson Capital Group Inc. reduced its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 1.7% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 178,761 shares of the medical equipment provider's stock after selling 3,039 shares during the quarter. Zimmer Biomet makes up 4.2% of Speece Thorson Capital Group Inc.'s portfolio, making the stock its 2nd biggest position. Speece Thorson Capital Group Inc. owned approximately 0.09% of Zimmer Biomet worth $20,232,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ZBH. Brighton Jones LLC bought a new position in shares of Zimmer Biomet in the 4th quarter worth about $204,000. Proficio Capital Partners LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth about $55,000. Raymond James Financial Inc. acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth about $21,234,000. AGF Management Ltd. acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth about $590,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Zimmer Biomet by 143.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,118 shares of the medical equipment provider's stock worth $224,000 after acquiring an additional 1,247 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of analyst reports. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the stock a "buy" rating in a report on Tuesday, May 6th. Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Evercore ISI dropped their price objective on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Raymond James Financial dropped their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a research note on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $110.00.

Zimmer Biomet Price Performance

Shares of ZBH traded down $1.27 during mid-day trading on Friday, hitting $93.88. The company's stock had a trading volume of 1,573,583 shares, compared to its average volume of 1,827,963. The firm has a 50-day moving average price of $93.21 and a 200 day moving average price of $101.31. The stock has a market capitalization of $18.57 billion, a price-to-earnings ratio of 20.77, a PEG ratio of 2.17 and a beta of 0.71. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The business's revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.94 EPS. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.02%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.39% of the stock is currently owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.